Citi Pharma (KAR:CPHL) Marketable Securities: ₨0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
15 GF Score
Price ₨72.36
! 1 Warning Sign
View Full Analysis

What is Citi Pharma Marketable Securities?

Citi Pharma KAR:CPHL -0.69% 15 Marketable Securities is ₨0.00 Mil as of . 20. GuruFocus rates KAR:CPHL with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Citi Pharma's Marketable Securities for the quarter that ended in . 20 was ₨0.00 Mil.

Citi Pharma  (KAR:CPHL) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Citi Pharma Marketable Securities Related Terms

Citi Pharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for Citi Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma Marketable Securities Chart

Citi Pharma Annual Data
Trend
Marketable Securities

Citi Pharma Semi-Annual Data
Marketable Securities
KAR:CPHL
15GF Score
Citi Pharma Ltd KAR:CPHL
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citi Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₨0.00 Mil mean?
Citi Pharma (KAR:CPHL) has a Marketable Securities of ₨0.00 Mil as of . 20. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Citi Pharma and its competitors.
Is Citi Pharma's Marketable Securities too high?
Citi Pharma's current Marketable Securities is ₨0.00 Mil. Overall, Citi Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Citi Pharma's Marketable Securities compare to ZTS and UTHR?
Citi Pharma's Marketable Securities of ₨0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Citi Pharma and its competitors. Citi Pharma's current Marketable Securities is ₨0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citi Pharma stock overvalued right now?
Citi Pharma (KAR:CPHL) has a current Marketable Securities of ₨0.00 Mil. The current Marketable Securities is ₨0.00 Mil. Citi Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Citi Pharma (KAR:CPHL), the current Marketable Securities is ₨0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
15GF Score

Get the complete analysis for KAR:CPHL

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨72.36
Price